While Cigna has been rebuffed for acquisitions in the past due to antitrust concerns, experts say a potential deal between the two private payers this time has some legs.
Subscribe to:
Post Comments (Atom)
< + > Real-Time Pharma Insights: Philip Poulidis on Scaling ODAIA AI – Life Sciences Today Podcast Episode 41
We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Philip Poulidis, ...
No comments:
Post a Comment